Salix Pharmaceuticals 在 ACG 2024 年度科学会议上展示了 Xifaxan 单药治疗与乳果糖治疗 OHE 复发和死亡率的疗效。 Salix Pharmaceuticals presents Xifaxan monotherapy vs lactulose for OHE recurrence and mortality at ACG 2024 Annual Scientific Meeting.

Bausch Health的子公司Salix制药公司将在ACG 2024年度科学会议上介绍研究结果。 Salix Pharmaceuticals, a subsidiary of Bausch Health, will present findings at the ACG 2024 Annual Scientific Meeting. 研究包括对Xifaxan® (利法西明) 单一治疗和乳糖的比较,以减少明显肝脑病变 (OHE) 的复发和死亡率进行特例分析. The research includes a post-hoc analysis comparing Xifaxan® (rifaximin) monotherapy and lactulose for reducing overt hepatic encephalopathy (OHE) recurrence and mortality. 此外,将分享新数据,说明OHE出院后,Xifaxan对再入院患者的影响. Additionally, new data on Xifaxan's effect on rehospitalizations after OHE discharge will be shared. 会议还将重点介绍关于普伦武的研究结果,这是一种肠胃准备药物。 The meeting will also feature findings on Plenvu, a bowel preparation medication.